trending Market Intelligence /marketintelligence/en/news-insights/trending/Lqr1zWUR86wNnpeLHTSumQ2 content esgSubNav
In This List

Seattle Genetics breast cancer drug well-tolerated in phase 1 trial

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Seattle Genetics breast cancer drug well-tolerated in phase 1 trial

Seattle Genetics Inc. said ladiratuzumab vedotin was well-tolerated in an ongoing phase 1 trial with metastatic triple negative breast cancer patients.

The study, conducted in 81 patients who had received prior systemic metastatic therapies, recorded a median progression-free survival of 11 weeks. Meanwhile, the median duration of response was 13.3 weeks.

Seattle Genetics reported a 25% objective response rate and 28% clinical benefit rate for 60 efficacy-evaluable patients.

The side effects in the trial included peripheral neuropathy, neutropenia and anemia.